Paola Mariglia

Rome, 00161, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation.

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation.

Journal: Journal of clinical medicine

Published: August 11, 2022

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.

Journal: Blood

Published: April 02, 2021

Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.

Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.

Journal: Blood

Published: March 26, 2021

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.

Journal: Frontiers in oncology

Published: December 02, 2020

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.

Journal: Haematologica

Published: October 05, 2020

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia.

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia.

Journal: Haematologica

Published: June 18, 2020

ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia.

ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia.

Journal: British journal of haematology

Published: April 26, 2020

Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.

Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.

Journal: British journal of haematology

Published: September 02, 2019

Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.

Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.

Journal: British journal of haematology

Published: May 31, 2018

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Journal: British journal of haematology

Published: May 23, 2018

Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.

Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 25, 2018

The antileukemic potential of natural killer cells.

The antileukemic potential of natural killer cells.

Journal: Immunotherapy

Published: March 15, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026